Long-Term Retention of ^sup 177^Lu/^sup 177m^Lu-DOTATATE in Patients Investigated by [gamma]-Spectrometry and [gamma]-Camera Imaging
Dosimetry in peptide receptor radionuclide therapy using ...-DOTATATE is based on patient imaging during the first week after administration and determination of the activity retention as a function of time for different tissues. For calculation of the absorbed dose, it is generally assumed that the...
Gespeichert in:
Veröffentlicht in: | The Journal of nuclear medicine (1978) 2015-07, Vol.56 (7), p.976 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 7 |
container_start_page | 976 |
container_title | The Journal of nuclear medicine (1978) |
container_volume | 56 |
creator | Gleisner, Katarina Sjögreen Brolin, Gustav Sundlöv, Anna Mjekiqi, Edita Östlund, Karl Tennvall, Jan Larsson, Erik |
description | Dosimetry in peptide receptor radionuclide therapy using ...-DOTATATE is based on patient imaging during the first week after administration and determination of the activity retention as a function of time for different tissues. For calculation of the absorbed dose, it is generally assumed that the long-term activity retention follows the pattern determined from the first week. This work aimed to investigate the validity of this assumption by performing additional patient measurements between 5 and 10 wk after administration. A further aim was to investigate to what extent absorbed dose values were affected when including these measurements, also taking into account the radionuclide impurity of ... and build-up of secondary ... from the ... decay. A combination of methods was used: planar ...-camera imaging as part of the clinical dosimetry protocol, determination of the whole-body activity between 5 and 9 wk after injection using spectrometric NaI(Tl) and HPGe detectors, and imaging between 5 and 10 wk after injection for assessment of the activity distribution. From these measurements the long-term retention of activity was determined and the relative influence on absorbed doses calculated. The most important finding was a clearly visualized tumor uptake in images from between 5 and 7 wk after injection and in 1 patient also kidney and spleen uptake in images acquired on day 33. As a consequence, the total-body time-activity curve had a tail, which was not completely captured by imaging during the first week. The absorbed doses to total body and tumors obtained when including these late time points were on average 5%-6% higher than those obtained when using data acquired during the first week. The contributions to the absorbed dose from ... and secondary ... were negligible. At approximately 5-7 wk after injection, there was a measureable amount of ...-DOTATATE in patients, which is mainly governed by retention in tumors. For tumor dosimetry, imaging at a later time than the routinely used 7 d may be warranted. The contribution to the absorbed dose from the radionuclide impurity of ... was negligible. (ProQuest: ... denotes formulae/symbols omitted.) |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1696044381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3742596701</sourcerecordid><originalsourceid>FETCH-proquest_journals_16960443813</originalsourceid><addsrcrecordid>eNqNTE1LAzEUDEWhq_Y_PPAcTNgmuz1KrVgoKLq30panfQ0pJlmTrNC7P9wc1LPMYWaYjxGrpKoVV1o3Z6wSUkuulFBjdpHSUQih27at2NcqeMM7ig6eKZPPNngIB9imoQfZNNvVcPOrXTH87rG7LViA9fCE2ZZJgqX_pJStwUx7eD3B2qBzuOEvPb3lGBzleAL0-79gjo4iwtKhsd5csfMDviea_PAlu75fdPMH3sfwMZTn3TEM0ZdoJ_VMi-m0bmX9v9Y3JvZRKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1696044381</pqid></control><display><type>article</type><title>Long-Term Retention of ^sup 177^Lu/^sup 177m^Lu-DOTATATE in Patients Investigated by [gamma]-Spectrometry and [gamma]-Camera Imaging</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Gleisner, Katarina Sjögreen ; Brolin, Gustav ; Sundlöv, Anna ; Mjekiqi, Edita ; Östlund, Karl ; Tennvall, Jan ; Larsson, Erik</creator><creatorcontrib>Gleisner, Katarina Sjögreen ; Brolin, Gustav ; Sundlöv, Anna ; Mjekiqi, Edita ; Östlund, Karl ; Tennvall, Jan ; Larsson, Erik</creatorcontrib><description>Dosimetry in peptide receptor radionuclide therapy using ...-DOTATATE is based on patient imaging during the first week after administration and determination of the activity retention as a function of time for different tissues. For calculation of the absorbed dose, it is generally assumed that the long-term activity retention follows the pattern determined from the first week. This work aimed to investigate the validity of this assumption by performing additional patient measurements between 5 and 10 wk after administration. A further aim was to investigate to what extent absorbed dose values were affected when including these measurements, also taking into account the radionuclide impurity of ... and build-up of secondary ... from the ... decay. A combination of methods was used: planar ...-camera imaging as part of the clinical dosimetry protocol, determination of the whole-body activity between 5 and 9 wk after injection using spectrometric NaI(Tl) and HPGe detectors, and imaging between 5 and 10 wk after injection for assessment of the activity distribution. From these measurements the long-term retention of activity was determined and the relative influence on absorbed doses calculated. The most important finding was a clearly visualized tumor uptake in images from between 5 and 7 wk after injection and in 1 patient also kidney and spleen uptake in images acquired on day 33. As a consequence, the total-body time-activity curve had a tail, which was not completely captured by imaging during the first week. The absorbed doses to total body and tumors obtained when including these late time points were on average 5%-6% higher than those obtained when using data acquired during the first week. The contributions to the absorbed dose from ... and secondary ... were negligible. At approximately 5-7 wk after injection, there was a measureable amount of ...-DOTATATE in patients, which is mainly governed by retention in tumors. For tumor dosimetry, imaging at a later time than the routinely used 7 d may be warranted. The contribution to the absorbed dose from the radionuclide impurity of ... was negligible. (ProQuest: ... denotes formulae/symbols omitted.)</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>CODEN: JNMEAQ</identifier><language>eng</language><publisher>New York: Society of Nuclear Medicine</publisher><subject>Dosimetry ; Nuclear medicine ; Patients ; Radiation therapy</subject><ispartof>The Journal of nuclear medicine (1978), 2015-07, Vol.56 (7), p.976</ispartof><rights>Copyright Society of Nuclear Medicine Jul 1, 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Gleisner, Katarina Sjögreen</creatorcontrib><creatorcontrib>Brolin, Gustav</creatorcontrib><creatorcontrib>Sundlöv, Anna</creatorcontrib><creatorcontrib>Mjekiqi, Edita</creatorcontrib><creatorcontrib>Östlund, Karl</creatorcontrib><creatorcontrib>Tennvall, Jan</creatorcontrib><creatorcontrib>Larsson, Erik</creatorcontrib><title>Long-Term Retention of ^sup 177^Lu/^sup 177m^Lu-DOTATATE in Patients Investigated by [gamma]-Spectrometry and [gamma]-Camera Imaging</title><title>The Journal of nuclear medicine (1978)</title><description>Dosimetry in peptide receptor radionuclide therapy using ...-DOTATATE is based on patient imaging during the first week after administration and determination of the activity retention as a function of time for different tissues. For calculation of the absorbed dose, it is generally assumed that the long-term activity retention follows the pattern determined from the first week. This work aimed to investigate the validity of this assumption by performing additional patient measurements between 5 and 10 wk after administration. A further aim was to investigate to what extent absorbed dose values were affected when including these measurements, also taking into account the radionuclide impurity of ... and build-up of secondary ... from the ... decay. A combination of methods was used: planar ...-camera imaging as part of the clinical dosimetry protocol, determination of the whole-body activity between 5 and 9 wk after injection using spectrometric NaI(Tl) and HPGe detectors, and imaging between 5 and 10 wk after injection for assessment of the activity distribution. From these measurements the long-term retention of activity was determined and the relative influence on absorbed doses calculated. The most important finding was a clearly visualized tumor uptake in images from between 5 and 7 wk after injection and in 1 patient also kidney and spleen uptake in images acquired on day 33. As a consequence, the total-body time-activity curve had a tail, which was not completely captured by imaging during the first week. The absorbed doses to total body and tumors obtained when including these late time points were on average 5%-6% higher than those obtained when using data acquired during the first week. The contributions to the absorbed dose from ... and secondary ... were negligible. At approximately 5-7 wk after injection, there was a measureable amount of ...-DOTATATE in patients, which is mainly governed by retention in tumors. For tumor dosimetry, imaging at a later time than the routinely used 7 d may be warranted. The contribution to the absorbed dose from the radionuclide impurity of ... was negligible. (ProQuest: ... denotes formulae/symbols omitted.)</description><subject>Dosimetry</subject><subject>Nuclear medicine</subject><subject>Patients</subject><subject>Radiation therapy</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqNTE1LAzEUDEWhq_Y_PPAcTNgmuz1KrVgoKLq30panfQ0pJlmTrNC7P9wc1LPMYWaYjxGrpKoVV1o3Z6wSUkuulFBjdpHSUQih27at2NcqeMM7ig6eKZPPNngIB9imoQfZNNvVcPOrXTH87rG7LViA9fCE2ZZJgqX_pJStwUx7eD3B2qBzuOEvPb3lGBzleAL0-79gjo4iwtKhsd5csfMDviea_PAlu75fdPMH3sfwMZTn3TEM0ZdoJ_VMi-m0bmX9v9Y3JvZRKw</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Gleisner, Katarina Sjögreen</creator><creator>Brolin, Gustav</creator><creator>Sundlöv, Anna</creator><creator>Mjekiqi, Edita</creator><creator>Östlund, Karl</creator><creator>Tennvall, Jan</creator><creator>Larsson, Erik</creator><general>Society of Nuclear Medicine</general><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>20150701</creationdate><title>Long-Term Retention of ^sup 177^Lu/^sup 177m^Lu-DOTATATE in Patients Investigated by [gamma]-Spectrometry and [gamma]-Camera Imaging</title><author>Gleisner, Katarina Sjögreen ; Brolin, Gustav ; Sundlöv, Anna ; Mjekiqi, Edita ; Östlund, Karl ; Tennvall, Jan ; Larsson, Erik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_16960443813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Dosimetry</topic><topic>Nuclear medicine</topic><topic>Patients</topic><topic>Radiation therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gleisner, Katarina Sjögreen</creatorcontrib><creatorcontrib>Brolin, Gustav</creatorcontrib><creatorcontrib>Sundlöv, Anna</creatorcontrib><creatorcontrib>Mjekiqi, Edita</creatorcontrib><creatorcontrib>Östlund, Karl</creatorcontrib><creatorcontrib>Tennvall, Jan</creatorcontrib><creatorcontrib>Larsson, Erik</creatorcontrib><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gleisner, Katarina Sjögreen</au><au>Brolin, Gustav</au><au>Sundlöv, Anna</au><au>Mjekiqi, Edita</au><au>Östlund, Karl</au><au>Tennvall, Jan</au><au>Larsson, Erik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Retention of ^sup 177^Lu/^sup 177m^Lu-DOTATATE in Patients Investigated by [gamma]-Spectrometry and [gamma]-Camera Imaging</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2015-07-01</date><risdate>2015</risdate><volume>56</volume><issue>7</issue><spage>976</spage><pages>976-</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><coden>JNMEAQ</coden><abstract>Dosimetry in peptide receptor radionuclide therapy using ...-DOTATATE is based on patient imaging during the first week after administration and determination of the activity retention as a function of time for different tissues. For calculation of the absorbed dose, it is generally assumed that the long-term activity retention follows the pattern determined from the first week. This work aimed to investigate the validity of this assumption by performing additional patient measurements between 5 and 10 wk after administration. A further aim was to investigate to what extent absorbed dose values were affected when including these measurements, also taking into account the radionuclide impurity of ... and build-up of secondary ... from the ... decay. A combination of methods was used: planar ...-camera imaging as part of the clinical dosimetry protocol, determination of the whole-body activity between 5 and 9 wk after injection using spectrometric NaI(Tl) and HPGe detectors, and imaging between 5 and 10 wk after injection for assessment of the activity distribution. From these measurements the long-term retention of activity was determined and the relative influence on absorbed doses calculated. The most important finding was a clearly visualized tumor uptake in images from between 5 and 7 wk after injection and in 1 patient also kidney and spleen uptake in images acquired on day 33. As a consequence, the total-body time-activity curve had a tail, which was not completely captured by imaging during the first week. The absorbed doses to total body and tumors obtained when including these late time points were on average 5%-6% higher than those obtained when using data acquired during the first week. The contributions to the absorbed dose from ... and secondary ... were negligible. At approximately 5-7 wk after injection, there was a measureable amount of ...-DOTATATE in patients, which is mainly governed by retention in tumors. For tumor dosimetry, imaging at a later time than the routinely used 7 d may be warranted. The contribution to the absorbed dose from the radionuclide impurity of ... was negligible. (ProQuest: ... denotes formulae/symbols omitted.)</abstract><cop>New York</cop><pub>Society of Nuclear Medicine</pub></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0161-5505 |
ispartof | The Journal of nuclear medicine (1978), 2015-07, Vol.56 (7), p.976 |
issn | 0161-5505 1535-5667 |
language | eng |
recordid | cdi_proquest_journals_1696044381 |
source | EZB-FREE-00999 freely available EZB journals |
subjects | Dosimetry Nuclear medicine Patients Radiation therapy |
title | Long-Term Retention of ^sup 177^Lu/^sup 177m^Lu-DOTATATE in Patients Investigated by [gamma]-Spectrometry and [gamma]-Camera Imaging |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T08%3A35%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Retention%20of%20%5Esup%20177%5ELu/%5Esup%20177m%5ELu-DOTATATE%20in%20Patients%20Investigated%20by%20%5Bgamma%5D-Spectrometry%20and%20%5Bgamma%5D-Camera%20Imaging&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Gleisner,%20Katarina%20Sj%C3%B6green&rft.date=2015-07-01&rft.volume=56&rft.issue=7&rft.spage=976&rft.pages=976-&rft.issn=0161-5505&rft.eissn=1535-5667&rft.coden=JNMEAQ&rft_id=info:doi/&rft_dat=%3Cproquest%3E3742596701%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1696044381&rft_id=info:pmid/&rfr_iscdi=true |